Denali Therapeutics (DNLI) EBIT (2017 - 2026)
Denali Therapeutics (DNLI) reported EBIT of -$137.4 million for Q1 2026, up 5.65% year-over-year from -$130.0 million in Q1 2025, and little changed on a QoQ basis from -$137.4 million in Q4 2025.
Denali Therapeutics (DNLI) has 10 years of EBIT data on file, last reported at -$137.4 million in Q1 2026.
- Quarterly EBIT rose 5.65% year-over-year to -$137.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$547.1 million (down 6.19% YoY) and the FY2025 annual result came in at -$555.3 million, down 13.95% from the prior year.
- EBIT steadied at -$137.4 million in Q1 2026 per DNLI's latest filing, from -$137.4 million in the prior quarter.
- Across five years, EBIT topped out at $170.5 million in Q2 2023 and bottomed at -$145.6 million in Q1 2025.
- The 5-year median for EBIT is -$120.8 million (2023), against an average of -$101.0 million.
- The widest annual swing landed in 2023, when EBIT surged 377.59%; it then plunged 168.39% in 2024.
- Tracing DNLI's EBIT over 5 years: stood at -$105.3 million in 2022, then declined by 25.85% to -$132.6 million in 2023, then gained by 2.06% to -$129.8 million in 2024, then slipped by 5.79% to -$137.4 million in 2025, then rose by 0.01% to -$137.4 million in 2026.
- Per Business Quant, the three latest DNLI EBIT figures stand at -$137.4 million (Q1 2026), -$137.4 million (Q4 2025), and -$137.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Denali Therapeutics | 3.82 Bn | 3.82 Bn | - | -137.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -137.36 Mn |
| Dec 31, 2025 | -137.37 Mn |
| Sep 30, 2025 | -137.43 Mn |
| Jun 30, 2025 | -134.96 Mn |
| Mar 31, 2025 | -145.58 Mn |
| Dec 31, 2024 | -129.85 Mn |
| Sep 30, 2024 | -123.19 Mn |
| Jun 30, 2024 | -116.59 Mn |
| Mar 31, 2024 | -117.72 Mn |
| Dec 31, 2023 | -132.57 Mn |
| Sep 30, 2023 | -113.80 Mn |
| Jun 30, 2023 | 170.48 Mn |
| Mar 31, 2023 | -120.82 Mn |
| Dec 31, 2022 | -105.34 Mn |
| Sep 30, 2022 | -107.49 Mn |
| Jun 30, 2022 | -61.42 Mn |
| Mar 31, 2022 | -66.50 Mn |
| Dec 31, 2021 | -77.12 Mn |
| Sep 30, 2021 | -85.59 Mn |
| Jun 30, 2021 | -61.82 Mn |
| Mar 31, 2021 | -71.22 Mn |
| Dec 31, 2020 | 244.08 Mn |
| Sep 30, 2020 | -60.12 Mn |
| Jun 30, 2020 | -61.28 Mn |
| Mar 31, 2020 | -59.97 Mn |
| Dec 31, 2019 | -57.76 Mn |
| Sep 30, 2019 | -50.16 Mn |
| Jun 30, 2019 | -62.76 Mn |
| Mar 31, 2019 | -42.51 Mn |
| Dec 31, 2018 | 74.72 Mn |
| Sep 30, 2018 | -37.96 Mn |
| Jun 30, 2018 | -57.38 Mn |
| Mar 31, 2018 | -25.75 Mn |
| Dec 31, 2017 | -23.54 Mn |
| Sep 30, 2017 | -22.29 Mn |
| Jun 30, 2017 | -22.57 Mn |
| Mar 31, 2017 | -21.74 Mn |